Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350963 | 1.00 | CYP1A2 (0.61) | CYP1A2SMN1; SMN2CYP2C19GRM2POLB | |
| SCHEMBL2031354 | 1.00 | CYP1A2 (0.61) | CYP1A2SMN1; SMN2CYP2C19GRM2POLB | |
| SCHEMBL30496322 | 1.00 | CYP1A2 (0.61) | CYP1A2SMN1; SMN2CYP2C19GRM2POLB | |
| SCHEMBL30496298 | 0.84 | ALDH1A1 (0.53) | SMN1; SMN2POLBKDM4EALDH1A1CD274 | |
| SCHEMBL2032215 | 0.83 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2CYP2C19GPBAR1ALDH1A1 | |
| SCHEMBL1820777 | 0.83 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2CYP2C19GPBAR1ALDH1A1 | |
| SCHEMBL1819248 | 0.83 | CYP1A2 (0.60) | CYP1A2SMN1; SMN2CYP2C19CD274 | |
| SCHEMBL1972076 | 0.83 | CYP1A2 (0.60) | CYP1A2SMN1; SMN2CYP2C19CD274 | |
| SCHEMBL2587055 | 0.83 | CYP1A2 (0.60) | CYP1A2SMN1; SMN2CYP2C19CD274 | |
| SCHEMBL2034260 | 0.83 | SMN1; SMN2 (0.61) | CYP1A2SMN1; SMN2CYP2C19TACR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-12214018-B2 | Glucose responsive insulins | PROTOMER TECHNOLOGIES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 1575/4885SMN1; SMN2 3585/4885CYP2C19 2922/4885 |
| US-12214018-B2 | Glucose responsive insulins | GLP1R, GPR119, IAPP | CYP1A2 4191/4885SMN1; SMN2 1263/4885CYP2C19 3886/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | CYP1A2 2895/4885SMN1; SMN2 1833/4885CYP2C19 258/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 2416/4885SMN1; SMN2 3352/4885CYP2C19 3287/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | CYP1A2 1625/4885SMN1; SMN2 3600/4885CYP2C19 3010/4885 |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 2416/4885SMN1; SMN2 3352/4885CYP2C19 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.